Cite
HARVARD Citation
Collins, G. et al. (2021). A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leukemia & lymphoma. 62 (11), pp. 2625-2636. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Collins, G. et al. (2021). A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leukemia & lymphoma. 62 (11), pp. 2625-2636. [Online].